Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.
about
Hemolytic uremic syndrome: new developments in pathogenesis and treatmentShiga Toxin (Stx) Classification, Structure, and FunctionBaicalin inhibits the lethality of ricin in mice by inducing protein oligomerization.Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.Shiga toxin pathogenesis: kidney complications and renal failure.Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.Progress towards recombinant anti-infective antibodies.Recent advances in understanding enteric pathogenic Escherichia coli.Antibody recognition of Shiga toxins (Stxs): computational identification of the epitopes of Stx2 subunit A to the antibodies 11E10 and S2C4The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide.Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteersInteraction between Shiga toxin and monoclonal antibodies: binding characteristics and in vitro neutralizing abilities.Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS)Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans.Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteersMonoclonal antibody 11E10, which neutralizes shiga toxin type 2 (Stx2), recognizes three regions on the Stx2 A subunit, blocks the enzymatic action of the toxin in vitro, and alters the overall cellular distribution of the toxin.Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013Targeting bacterial toxins.Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.Isolation of B subunit-specific monoclonal antibody clones that strongly neutralize the toxicity of Shiga toxin 2.ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression.Shiga Toxin Therapeutics: Beyond Neutralization.Rapid detection of Shiga toxin-producing Escherichia coli by optical immunoassay.
P2860
Q24613517-CDEF4D47-EB98-42FD-B551-7FC9F51D6123Q27021676-39481CB2-C07B-4033-9D32-71E94CEAE2C1Q30373440-D2ADB630-77B9-461B-B3B7-D0800590C1BFQ33380705-2D4AEC69-5FBB-4D54-B94E-B35E6044D778Q33397541-8587CD75-2E64-4A54-9FCB-1FA5C7F95592Q33404149-1EC9A16A-AC00-4E7D-AEE4-223B61B199D7Q33410645-3E2399F6-A5E3-4AA1-8BD9-99515EE244B1Q33418526-DD68C9C0-99F3-4A6A-ADB5-C2A83F11AD7BQ33568256-C1C9BB52-D7A8-4604-B56E-27EE2EB323B1Q34375210-7660E774-0C4F-4EBE-93DB-3B1D5FD663F2Q35091607-29556FB3-75B2-4E6C-A873-34D171826F20Q35220377-5C975F65-AAAD-4F30-8917-1ED921880D0FQ35221158-BE5A46F5-29D1-454A-A5BB-4C6639E871ADQ36215915-AE28828C-D68F-4090-B6AC-0FFBE5B3EEB6Q36329665-758875FB-8BA4-44DE-A21C-7353ED29FD62Q36841541-E2C773EE-7769-448D-A5A7-6D69DBFA4A11Q37064733-64A95BE7-CFCF-4271-95EB-954BA5FE57A5Q37077633-EEB6C01C-5939-4083-829B-8386F0682DA4Q37247682-3F130599-893A-46B8-B000-906E88E118A1Q37256478-056787E8-25EB-4855-9ABB-9067EC91055EQ37496388-EFFF14EA-C9CA-4C10-943E-8A2A5586C005Q37996325-DE52831B-987D-4FA7-A95A-8531FB411AEEQ38024274-FED4E950-3268-44DA-9E5D-63B8DC1F2B23Q38927469-8A4E8BA8-7A4D-424F-8F39-E91CF20D114EQ40003950-C34039A2-D0E3-4E23-8829-37F988099C9FQ41669177-4B663307-4B36-4471-89CC-D8C14BBFA80FQ42637879-B447C5C1-2788-4331-9535-D9961A7555EA
P2860
Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Phase 1 safety and pharmacokin ...... y to healthy adult volunteers.
@ast
Phase 1 safety and pharmacokin ...... y to healthy adult volunteers.
@en
type
label
Phase 1 safety and pharmacokin ...... y to healthy adult volunteers.
@ast
Phase 1 safety and pharmacokin ...... y to healthy adult volunteers.
@en
prefLabel
Phase 1 safety and pharmacokin ...... y to healthy adult volunteers.
@ast
Phase 1 safety and pharmacokin ...... y to healthy adult volunteers.
@en
P2093
P2860
P1476
Phase 1 safety and pharmacokin ...... ly to healthy adult volunteers
@en
P2093
Angela Melton-Celsa
Carol O Tacket
Claire Thuning-Roberson
David G Young
Pierre A Chavaillaz
Robert Edelman
P2860
P304
P356
10.1128/AAC.49.5.1808-1812.2005
P407
P577
2005-05-01T00:00:00Z